MCK’s HCIT Segment Has Shown Strong Momentum In Recent Bookings

Analysts at Goldman Sachs reiterate their "buy" rating on McKesson Corp MCK. The target price for MCK is set to $86. The management has provided an update on the business and reaffirmed fiscal 2011 guidance at the investor day yesterday. The key takeaways for the analysts included: “(1) market leading position in US pharma distribution with solid exposure to customers which buy generics from McKesson. Specifically, it sees an opportunity to increase penetration of its generic program which will become increasingly important as we move into a period of record generic launches. (2) HCIT segment has shown strong recent bookings momentum and is positioned for future growth due to the impact of health reform and the federal stimulus package. (3) Medical- Surgical unit continues to be a leader in the alternate site market, and the company believes that high fragmentation in the space presents significant opportunities for consolidation,” the analysts mention. More Analyst Ratings here